ArticleJournal of the American Chemical Society2018
Nitric Oxide-Releasing Cyclodextrins.
Article in Journal of the American Chemical Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 104 citations in OpenAlex.
- Elastic circular organic microcrystals prepared by photoinduced delamination.Nature communications · 2025Article
- Nitric Oxide-Releasing Topical Treatments for Cutaneous Melanoma.Molecular pharmaceutics · 2024Article
- Nanoarchitectonics of nitric oxide releasing supramolecular structures for enhanced antibacterial efficacy under visible light irradiation.Journal of colloid and interface science · 2023Article
- Antibacterial gas therapy: Strategies, advances, and prospects.Bioactive materials · 2023Review
- Injectable polysaccharide hydrogels as localized nitric oxide delivery formulations.Advanced materials technologies · 2023Article
- Cyclodextrins as eminent constituents in nanoarchitectonics for drug delivery systems.Beilstein journal of nanotechnology · 2023Review
- Role of Nitric Oxide-Releasing Glycosaminoglycans in Wound Healing.ACS biomaterials science & engineering · 2022Article
- Nitric oxide boosters as defensive agents against COVID-19 infection: an opinion.Journal of biomolecular structure & dynamics · 2022Article
- Recent Developments in Nitric Oxide Donors and Delivery for Antimicrobial and Anti-Biofilm Applications.Molecules (Basel, Switzerland) · 2022Review
- Β-Cyclodextrin-graft-poly(amidoamine) dendrons as the nitric oxide deliver system for the chronic rhinosinusitis therapy.Drug delivery · 2021Article
- Therapeutic Delivery of Nitric Oxide Utilizing Saccharide-Based Materials.ACS applied materials & interfaces · 2021Review
- Efficient Persistent Luminescence Tuning Using a Cyclodextrin Inclusion Complex as Efficient Light Conversion Materials.ACS omega · 2021Article
- Nitric Oxide-Releasing Hyaluronic Acid as an Antibacterial Agent for Wound Therapy.Biomacromolecules · 2021Article
- Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections.F1000Research · 2021Review
- Modulation of the lifespan ofChemical science · 2020Article
- Complexation of methyl salicylate with β-cyclodextrin and its release characteristics for active food packaging.Food science and biotechnology · 2020Article
- High-efficiency dynamic sensing of biothiols in cancer cells with a fluorescent β-cyclodextrin supramolecular assembly.Chemical science · 2020Article
- A multifunctional platform with single-NIR-laser-triggered photothermal and NO release for synergistic therapy against multidrug-resistant Gram-negative bacteria and their biofilms.Journal of nanobiotechnology · 2020Article
- Light-triggered nitric oxide (NO) release from photoresponsive polymersomes for corneal wound healing.Chemical science · 2020Article
- Crystal-facet-dependent denitrosylation: modulation of NO release fromChemical science · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
A series of secondary amine-modified cyclodextrin (CD) derivatives was synthesized with diverse exterior terminal groups (i.e., hydroxyl, methyl, methoxyl, and primary amine). Subsequent reaction with nitric oxide (NO) gas under alkaline conditions yielded N-diazeniumdiolate-modified CD derivatives. Adjustable NO payloads (0.6-2.4 μmol/mg) and release half-lives (0.7-4.2 h) were achieved by regulating both the amount of secondary amine precursors and the functional groups around the NO donors. The bactericidal action of these NO-releasing cyclodextrin derivatives was evaluated against Pseudomonas aeruginosa, a Gram-negative pathogen, with antibacterial activity proving dependent on both the NO payload and exterior modification. Materials containing a high density of NO donors or primary amines exhibited the greatest ability to eradicate P. aeruginosa. Of the materials prepared, only the primary amine-terminated heptasubstituted CD derivatives exhibited toxicity against mammalian L929 mouse fibroblast cells. The NO donor-modified CD was also capable of delivering promethazine, a hydrophobic drug, thus demonstrating potential as a dual-drug-releasing therapeutic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.